Novo Nordisk Earnings Are Here. Wegovy Sales Beat Estimates for Weight Loss Drug.
Novo Nordisk posted solid quarterly results Wednesday before the market open.The drug maker’s sales came in at 71.3 billion ...
Novo Nordisk reports 24% sales jump, driven by diabetes and obesity treatments
Novo Nordisk (NYSE:NVO) (CSE:NOVOb) reported strong growth for the first nine months of 2024, with sales jumping by 23% in Danish kroner and 24% at constant exchange rates, reaching DKK 204.7 billion.
Novo Nordisk maintains booming sales of obesity and diabetes drugs
The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...
Novo Nordisk posts Q3 sales of obesity drug Wegovy above forecast
Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...